Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA
- PMID: 10216145
- DOI: 10.1002/hep.510290529
Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA
Abstract
Because interferon therapy exhibits low efficacy for cirrhotic patients infected with hepatitis C virus, this prospective study was conducted to determine effective interferon regimens tailored to treatment response by monitoring HCV RNA status. A total of 157 cirrhotic patients were enrolled to receive 9 million units (MU) of interferon three times a week. The HCV RNA values were drawn 8 weeks apart and the patients were randomized to a further 16 or 32 weeks of treatment after two sequential findings of negativity for HCV RNA. A total of 73 out of 157 patients (46%) proceeded to randomization to different durations of treatment, 37 short-course and 36 long-course (duration: 38 +/- 8 and 49 +/- 13 weeks; total amount of interferon: 940 +/- 240 and 1130 +/- 390 MU, respectively). The remaining 84 patients without two sequential negative serum HCV RNA determinations received 44.8 +/- 27.4 weeks of interferon (IFN) therapy with total amount of 993 +/- 633 MU. Of these 157 patients, sustained virological and biochemical response was shown in 32 (20%) and 37 patients (24%), respectively. Sustained virological and biochemical response rate in the randomized patients was significantly higher than in nonrandomized patients (41% vs. 2%, and 38% vs. 11%; each P <.01). Of the 73 randomized patients, the rate of sustained virological response in patients with long-course treatment (50%) was significantly higher than that of patients with short-course treatment (32%) (P =.026: log-rank test), and in patients with early disappearance of HCV RNA especially within 8 weeks, in patients with low virus load (</=10(6.3) copies/mL) and with HCV 2a. Multivariate analysis revealed that HCV RNA level and subtypes were the most important factors contributing to sustained virological response. Interferon is effective even in cirrhotic patients with low viral load and HCV 2a, but requires a longer course of administration.
Similar articles
-
Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.Hepatogastroenterology. 2002 Sep-Oct;49(47):1373-6. Hepatogastroenterology. 2002. PMID: 12239945
-
Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.J Gastroenterol. 2003;38(2):158-63. doi: 10.1007/s005350300026. J Gastroenterol. 2003. PMID: 12640530 Clinical Trial.
-
Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.Ital J Gastroenterol Hepatol. 1997 Jun;29(3):255-61. Ital J Gastroenterol Hepatol. 1997. PMID: 9646218
-
Therapy of hepatitis C: patients with cirrhosis.Hepatology. 1997 Sep;26(3 Suppl 1):128S-132S. doi: 10.1002/hep.510260722. Hepatology. 1997. PMID: 9305677 Review.
-
[Treatment response in chronic hepatitis C. Content of virus in serum is decisive for the outcome].Lakartidningen. 1998 Jan 7;95(1-2):40-3. Lakartidningen. 1998. PMID: 9458644 Review. Swedish.
Cited by
-
High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group.Dig Dis Sci. 2000 Dec;45(12):2414-21. doi: 10.1023/a:1005655428563. Dig Dis Sci. 2000. PMID: 11258568 Clinical Trial.
-
Is laparoscopy an advantage in the diagnosis of cirrhosis in chronic hepatitis C virus infection?World J Gastroenterol. 2003 Apr;9(4):745-50. doi: 10.3748/wjg.v9.i4.745. World J Gastroenterol. 2003. PMID: 12679924 Free PMC article.
-
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.Gut. 2000 Jul;47(1):131-6. doi: 10.1136/gut.47.1.131. Gut. 2000. PMID: 10861275 Free PMC article.
-
Role of hematopoietic growth factors as adjuncts in the treatment of chronic hepatitis C patients.Saudi J Gastroenterol. 2008 Jul;14(3):151-7. doi: 10.4103/1319-3767.41739. Saudi J Gastroenterol. 2008. PMID: 19568529 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials